Windtree Therapeutics (NASDAQ:WINT) Announces Earnings Results

Windtree Therapeutics (NASDAQ:WINT) issued its quarterly earnings results on Monday. The company reported ($20.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($8.11) by ($12.80), Zacks reports.

Windtree Therapeutics Stock Up 2.0 %

Windtree Therapeutics stock opened at $11.22 on Wednesday. Windtree Therapeutics has a 52-week low of $2.81 and a 52-week high of $27.00. The firm has a market cap of $6.64 million, a PE ratio of -0.31 and a beta of 0.55. The company’s 50 day moving average is $5.81 and its two-hundred day moving average is $5.71.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product is istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.